Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 108

Similar articles for PubMed (Select 23588560)

1.

Population pharmacokinetic analysis of tacrolimus in the first year after pediatric liver transplantation.

Guy-Viterbo V, Scohy A, Verbeeck RK, Reding R, Wallemacq P, Musuamba FT.

Eur J Clin Pharmacol. 2013 Aug;69(8):1533-42. doi: 10.1007/s00228-013-1501-0. Epub 2013 Apr 16.

PMID:
23588560
2.

Population pharmacokinetic analysis of tacrolimus early after pediatric liver transplantation.

Musuamba FT, Guy-Viterbo V, Reding R, Verbeeck RK, Wallemacq P.

Ther Drug Monit. 2014 Feb;36(1):54-61. doi: 10.1097/FTD.0b013e31829dcbcd.

PMID:
24081207
3.

A simultaneous d-optimal designed study for population pharmacokinetic analyses of mycophenolic Acid and tacrolimus early after renal transplantation.

Musuamba FT, Mourad M, Haufroid V, Demeyer M, Capron A, Delattre IK, Delaruelle F, Wallemacq P, Verbeeck RK.

J Clin Pharmacol. 2012 Dec;52(12):1833-43. doi: 10.1177/0091270011423661. Epub 2011 Dec 29.

PMID:
22207766
4.

Population pharmacokinetics of tacrolimus in whole blood and plasma in asian liver transplant patients.

Sam WJ, Tham LS, Holmes MJ, Aw M, Quak SH, Lee KH, Lim SG, Prabhakaran K, Chan SY, Ho PC.

Clin Pharmacokinet. 2006;45(1):59-75.

PMID:
16430311
5.

Population pharmacokinetics of tacrolimus in pediatric liver transplantation: early posttransplantation clearance.

Wallin JE, Bergstrand M, Wilczek HE, Nydert PS, Karlsson MO, Staatz CE.

Ther Drug Monit. 2011 Dec;33(6):663-72. doi: 10.1097/FTD.0b013e31823415cc.

PMID:
22105583
6.

Tacrolimus pharmacokinetics in the early post-liver transplantation period and clinical applicability via Bayesian prediction.

Oteo I, Lukas JC, Leal N, Suarez E, Valdivieso A, Gastaca M, Ortiz de Urbina J, Calvo R.

Eur J Clin Pharmacol. 2013 Jan;69(1):65-74. doi: 10.1007/s00228-012-1300-z. Epub 2012 Jun 3.

PMID:
22660442
7.

Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation.

Monchaud C, de Winter BC, Knoop C, Estenne M, Reynaud-Gaubert M, Pison C, Stern M, Kessler R, Guillemain R, Marquet P, Rousseau A.

Clin Pharmacokinet. 2012 Mar 1;51(3):175-86. doi: 10.2165/11594760-000000000-00000.

PMID:
22339449
8.

Population pharmacokinetic analysis of tacrolimus early after Chinese pediatric liver transplantation.

Yang JW, Liao SS, Zhu LQ, Zhao Y, Zhang Y, Sun XY, Rao W, Qu W, Li WZ, Sun LY.

Int J Clin Pharmacol Ther. 2015 Jan;53(1):75-83. doi: 10.5414/CP202189.

PMID:
25207550
9.

Pharmacokinetics of sirolimus and tacrolimus in pediatric transplant patients.

Schubert M, Venkataramanan R, Holt DW, Shaw LM, McGhee W, Reyes J, Webber S, Sindhi R.

Am J Transplant. 2004 May;4(5):767-73.

10.

Influence of donor-recipient CYP3A4/5 genotypes, age and fluconazole on tacrolimus pharmacokinetics in pediatric liver transplantation: a population approach.

Guy-Viterbo V, Baudet H, Elens L, Haufroid V, Lacaille F, Girard M, Debray D, Chardot C, Reding R, Wallemacq P, Musuamba F.

Pharmacogenomics. 2014 Jun;15(9):1207-21. doi: 10.2217/pgs.14.75.

PMID:
25141896
11.

Tacrolimus dose individualization in "de novo" patients after 10 years of experience in liver transplantation: pharmacokinetic considerations and patient pathophysiology.

Valdivieso N, Oteo I, Valdivieso A, Lukas JC, Leal N, Gastaca M, de Urbina JO, Calvo R, Suarez E.

Int J Clin Pharmacol Ther. 2013 Jul;51(7):606-14. doi: 10.5414/CP201800.

PMID:
23735178
12.

Time of drug administration, CYP3A5 and ABCB1 genotypes, and analytical method influence tacrolimus pharmacokinetics: a population pharmacokinetic study.

Musuamba FT, Mourad M, Haufroid V, Delattre IK, Verbeeck RK, Wallemacq P.

Ther Drug Monit. 2009 Dec;31(6):734-42. doi: 10.1097/FTD.0b013e3181bf8623.

PMID:
19855314
13.

Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation.

Benkali K, Rostaing L, Premaud A, Woillard JB, Saint-Marcoux F, Urien S, Kamar N, Marquet P, Rousseau A.

Clin Pharmacokinet. 2010 Oct;49(10):683-92. doi: 10.2165/11535950-000000000-00000.

PMID:
20818834
14.

Population pharmacokinetic estimation of tacrolimus apparent clearance in adult liver transplant recipients.

Zahir H, McLachlan AJ, Nelson A, McCaughan G, Gleeson M, Akhlaghi F.

Ther Drug Monit. 2005 Aug;27(4):422-30.

PMID:
16044097
15.

Circadian and time-dependent variability in tacrolimus pharmacokinetics.

Park SI, Felipe CR, Pinheiro-Machado PG, Garcia R, Tedesco-Silva H Jr, Medina-Pestana JO.

Fundam Clin Pharmacol. 2007 Apr;21(2):191-7.

PMID:
17391292
16.

Population pharmacokinetics of tacrolimus in Asian paediatric liver transplant patients.

Sam WJ, Aw M, Quak SH, Lim SM, Charles BG, Chan SY, Ho PC.

Br J Clin Pharmacol. 2000 Dec;50(6):531-41.

17.
18.

The impact of sulfonylureas on tacrolimus apparent clearance revealed by a population pharmacokinetics analysis in Chinese adult liver-transplant patients.

Zhang XQ, Wang ZW, Fan JW, Li YP, Jiao Z, Gao JW, Peng ZH, Liu GL.

Ther Drug Monit. 2012 Apr;34(2):126-33. doi: 10.1097/FTD.0b013e31824a67eb.

PMID:
22377746
19.

Population pharmacokinetics of tacrolimus in children who receive cut-down or full liver transplants.

Staatz CE, Taylor PJ, Lynch SV, Willis C, Charles BG, Tett SE.

Transplantation. 2001 Sep 27;72(6):1056-61.

PMID:
11579300
20.

Pathophysiological idiosyncrasies and pharmacokinetic realities may interfere with tacrolimus dose titration in liver transplantation.

Oteo I, Lukas JC, Leal N, Suarez E, Valdivieso A, Gastaca M, de Urbina JO, Calvo R.

Eur J Clin Pharmacol. 2011 Jul;67(7):671-9. doi: 10.1007/s00228-011-0998-3. Epub 2011 Feb 17.

PMID:
21327908
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk